Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection

The treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has rapidly evolved over the past 5 years. Although androgen-deprivation therapy is still the backbone of treatment, the addition of docetaxel or abiraterone acetate has improved outcomes for patients with mHSPC and bec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: R. A. Gafanov, A. G. Dzidzaria, I. B. Kravtsov, S. V. Fastovets
Formato: Artigo
Idioma:Russo
Publicado em: ABV-press 2018-12-01
Colecção:Onkourologiâ
Assuntos:
metastatic hormone-sensitive prostate cancer
androgen-deprivation therapy
docetaxel
abiraterone
enzalutamide
Acesso em linha:https://oncourology.abvpress.ru/oncur/article/view/910
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados